Ashvattha Therapeutics Presents Preclinical Data on anti-VEGF Nanomedicine D-4517.2 at the 2023 ARVO…
<!-- Name:DistributionId Value:8825608 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…
Browsing Tag
AntiVEGF
Anti-VEGF Market Size is projected to reach USD 13.54 Billion by 2030, growing at a CAGR of 1.02%:…
New York, United States, July 21, 2022 (GLOBE NEWSWIRE) -- Vascular endothelial Growth factor, also known as VEGF, is a naturally occurring protein in the human body responsible for forming and maintaining new blood vessels. Under…
Continuous-Release Anti-VEGF for Macular Degeneration Continues to Impress
SAN ANTONIO -- An ocular implant that provided 6 months of continuous-release anti-VEGF therapy achieved vision and anatomic outcomes equivalent to standard monthly intravitreal…
Bispecific Antibody Compares Favorably With Anti-VEGF for Retinal Disease
SAN ANTONIO -- The bispecific antibody faricimab performed at least as well as standard anti-VEGF therapy for age-related macular degeneration (AMD) and diabetic macular edema…
Adverum Presents 2-Year OPTIC Data Demonstrating Sustained Durability and Promising Safety Profile…
-- Results featured in a presentation today at the Retina Society’s 54th Annual Scientific Meeting -- -- Robust aflibercept protein expression sustained through 2 years -- -- Over 80% reduction in annualized anti-VEGF injection…
Anti-VEGF Injections Preserved Vision in Severe Diabetic Retinopathy
Intravitreal injections of a vascular endothelial growth factor (VEGF) inhibitor reduced disease severity and vision-threatening complications in…